- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Azitra announces $1.5 million private placement at premium to market | 1 | Investing.com | ||
| 13.11. | Azitra reports Q3 results | 1 | Seeking Alpha | ||
| AZITRA Aktie jetzt für 0€ handeln | |||||
| 12.11. | Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates | 74 | PR Newswire | BRANFORD, Conn., Nov. 12, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 12.11. | Azitra, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | Azitra, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11. | Azitra denies report of $44 million direct offering, stock drops | 11 | Seeking Alpha | ||
| 07.11. | Azitra denies false report of $44 million registered direct offering | 2 | Investing.com | ||
| 07.11. | Azitra, Inc. Addresses False Report Regarding Sale of Securities | 55 | PR Newswire | BRANFORD, Conn., Nov. 7, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies... ► Artikel lesen | |
| 20.10. | Azitra stock soars after positive preclinical data for ichthyosis treatment | 2 | Investing.com | ||
| 20.10. | Azitra-Aktie schießt nach positiven präklinischen Daten für Hauttherapie in die Höhe | 5 | Investing.com Deutsch | ||
| 20.10. | Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris | 122 | PR Newswire | ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis vulgaris
Preclinical data show production of active... ► Artikel lesen | |
| 03.10. | Azitra erhält Non-Compliance-Mitteilung der NYSE American | 1 | Investing.com Deutsch | ||
| 03.10. | Azitra receives notice of non-compliance from NYSE American | 1 | Seeking Alpha | ||
| 03.10. | Azitra, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.10. | Azitra receives NYSE American non-compliance notice | 1 | Investing.com | ||
| 03.10. | Azitra, Inc.: Azitra Receives Notice of Non-Compliance from NYSE American | 161 | PR Newswire | BRANFORD, Conn., Oct. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies... ► Artikel lesen | |
| 29.08. | Azitra, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 29.08. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Azitra stock soars after first patient dosed in Phase 1/2 trial | 3 | Investing.com | ||
| 27.08. | Azitra doses first patient in phase 1/2 trial for cancer therapy rash | 2 | Investing.com |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 73,02 | -2,59 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 | ||
| QIAGEN | 41,790 | +1,79 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,57 | +0,56 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| JANUX THERAPEUTICS | 34,700 | +10,11 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 184,03 | -3,83 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| ADMA BIOLOGICS | 19,185 | +4,72 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 26,060 | +4,01 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,700 | +4,48 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,365 | +0,46 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| DYNE THERAPEUTICS | 20,820 | -3,92 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| NUVALENT | 109,92 | +0,50 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,690 | +2,98 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| ARS PHARMACEUTICALS | 9,305 | +15,73 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) | $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,130 | -1,06 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,80 | +4,41 % | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen |
Das Unternehmen AZITRA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,315 Euro und damit -3,90 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AZITRA INC finden Sie auf Wallstreet Online.